- Home
- SNSE vs THAR Comparison
SNSE vs THAR Comparison
Compare SNSE & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- THAR
- Stock Information
- Founded
- SNSE 2005
- THAR 2017
- Country
- SNSE United States
- THAR United States
- Employees
- SNSE N/A
- THAR N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- THAR Health Care
- Exchange
- SNSE Nasdaq
- THAR Nasdaq
- Market Cap
- SNSE 14.5M
- THAR 16.8M
- IPO Year
- SNSE 2021
- THAR 2022
- Fundamental
- Price
- SNSE $11.71
- THAR $2.87
- Analyst Decision
- SNSE Strong Buy
- THAR Strong Buy
- Analyst Count
- SNSE 4
- THAR 1
- Target Price
- SNSE $72.50
- THAR $17.00
- AVG Volume (30 Days)
- SNSE 56.5K
- THAR 363.3K
- Earning Date
- SNSE 11-13-2025
- THAR 11-06-2025
- Dividend Yield
- SNSE N/A
- THAR N/A
- EPS Growth
- SNSE N/A
- THAR N/A
- EPS
- SNSE N/A
- THAR N/A
- Revenue
- SNSE N/A
- THAR N/A
- Revenue This Year
- SNSE N/A
- THAR N/A
- Revenue Next Year
- SNSE N/A
- THAR N/A
- P/E Ratio
- SNSE N/A
- THAR N/A
- Revenue Growth
- SNSE N/A
- THAR N/A
- 52 Week Low
- SNSE $5.00
- THAR $0.95
- 52 Week High
- SNSE $18.35
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- SNSE 53.46
- THAR 46.33
- Support Level
- SNSE $11.00
- THAR $2.79
- Resistance Level
- SNSE $18.35
- THAR $3.30
- Average True Range (ATR)
- SNSE 1.55
- THAR 0.26
- MACD
- SNSE 0.36
- THAR -0.00
- Stochastic Oscillator
- SNSE 27.83
- THAR 11.56
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.